• MBX Biosciences posted a Q2 net loss of USD 37.1 million, widening from USD 19.4 million a year earlier.
• R&D expense rose 75.14% to USD 31 million, due to canvuparatide Phase 3 start-up costs and ongoing canvuparatide and MBX 4291 trials.
• G&A expense more than doubled to USD 9.9 million on higher personnel-related costs tied to expansion of leadership and infrastructure.
• Cash, cash equivalents and marketable securities totaled USD 418.6 million at June 30; management expects funding to last into 2029.
• Phase 3 canvuparatide trial is recruiting for a Q3 start; CEO Steve Hoerter highlighted early MBX 4291 data supporting once-monthly dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336841), on August 06, 2026, and is solely responsible for the information contained therein.